Key facts
- This page summarizes Albert Robichaud's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 Jun 2021, 09:12.
Albert Robichaud - 15 Jun 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- SAGE
- Reported as of
- 15 Jun 2021
- Net transaction value
- -$67,267
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2021, 09:12:54 UTC
- Next SEC filing
- 21 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Albert Robichaud
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Albert Robichaud filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 17 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$67,267.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SAGE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,000
- Change %
- +2.9%
- Price
- $0.000000
- Shares after
- 140,795
- Date
- 15 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
SAGE
transaction
Common Stock
Tax liability
- Transaction value
- $67,267
- Shares
- -1,144
- Change %
- -0.81%
- Price
- $58.80
- Shares after
- 139,651
- Date
- 15 Jun 2021
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On March 25, 2020, the reporting person was granted Performance Stock Units (PSU) to acquire a total of 10,000 shares of common stock. The PSU vests upon the achievement of certain milestones, one of which was met on June 15, 2021, resulting in the vesting of the PSU as to 4,000 shares.
Footnote F2
Reflects beneficial ownership balance, which includes 54 shares purchased on December 31, 2019 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan (the "ESPP") and 341 shares purchased on June 30, 2020 under the ESPP.